After controlling for other factors, a
generic drug in the highest marketing
competition group was expected to see a decrease of 32 percent in price over the study period, while a
generic drug in the lowest market
competition was expected to see a price increase of 47 percent over the
same period.
Currently, Canada is the only country that allows brand name pharmaceutical companies to sue
generic pharmaceutical companies multiple times on the
same patents, adding to the costs and risks of bringing
generic drug
competition to the Canadian market.